Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Neurology antibodies target proteins involved in neurodegeneration, neuropathic pain and migraine signaling. Aducanumab, gantenerumab and donanemab bind aggregated forms of amyloid beta (Aβ), each with a different preference for oligomers, fibrils or plaque species. Fremanezumab and galcanezumab neutralize calcitonin gene-related peptide (CGRP), whereas erenumab blocks the CGRP receptor. Tanezumab neutralizes nerve growth factor (NGF), a key mediator of nociceptor sensitization in inflammatory pain models. Further antibodies bind tau, alpha-synuclein and axon-growth inhibitors such as myelin-associated glycoprotein and repulsive guidance molecule A.
Luvagrobart is a human IgG1 κ monoclonal antibody targeting nerve growth factor (NGF). For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.
Bocunebart is a humanized monoclonal antibody designed to target human ADCYAP1, also known as adenylate cyclase-activating polypeptide (PACAP). By specifically binding to ADCYAP1, Bocunebart effectively inhibits the associated inflammatory signaling pathways, exhibiting potent anti-inflammatory activity. This antibody is particularly valuable for research focused on inflammation-related diseases, offering significant insights into the modulation of inflammatory responses.
Synonyms: DLX212
The Anti-beta Amyloid Antibody DLX212 specifically targets the beta-amyloid protein, which is a principal constituent of the amyloid plaques characteristic of Alzheimer’s disease pathology. This antibody is designed for use in research focused on the detection, quantification, and characterization of beta-amyloid aggregates in neurological studies.
Synonyms: CNTO 2125
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Amyloid Beta (Aβ) peptides. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Anti-Amyloid Beta Antibody (CNTO 2125) is essential for research focusing on Alzheimer's disease and other amyloid-related disorders, providing a crucial tool for the detection and quantification of Amyloid Beta peptides.
Erenumab is a fully human monoclonal antibody designed to selectively target and inhibit the calcitonin gene-related peptide (CGRP) receptor. This inhibition is crucial for the prevention of episodic migraine, as it interferes with the pathway believed to play a key role in the initiation of migraine episodes. Erenumab is specifically developed for prophylactic applications, offering a therapeutic approach for patients suffering from frequent migraine attacks.
Synonyms: UCB 0107
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody designed to specifically bind to a central tau epitope, encompassing amino acids 235-250. This antibody is particularly useful in the study of Alzheimer’s disease (AD), offering potential insights into disease mechanisms and pathways influenced by tau protein aggregation. Bepranemab's targeted binding affinity makes it a valuable tool for researchers focusing on the pathological features of AD and related tauopathies.
Synonyms: RG 6100; RO7105705; MTAU-9937A
Semorinemab (RG 6100) is a humanized IgG4 monoclonal antibody designed to specifically target the N-terminal region of the Tau protein, encompassing amino acid residues 6-23. This antibody exhibits a high affinity for human Tau, with a dissociation constant (Kd) of 3.8 nM, indicating robust binding efficiency. Semorinemab is primarily utilized in the investigation of Alzheimer's Disease, serving as a critical tool in research focused on the pathophysiology and potential therapeutic interventions for tauopathies.
Usilnetug is a human IgG1 κ monoclonal antibody targeting amyloid precursor protein (APP). For control experiments, it is recommended to use Human IgG1 kappa Isotype Control.
Synonyms: Mab158
Lecanemab (Mouse IgG2a) is a monoclonal antibody engineered to target soluble β-amyloid, a key player in the pathogenesis of Alzheimer's disease. This antibody is designed to mitigate cognitive decline by interacting with β-amyloid peptides. The variable region of Lecanemab (Mouse IgG2a) mirrors that of the original Lecanemab, ensuring specificity and efficacy in targeting, while its constant region is derived from the Mouse IgG2a sequence, facilitating its use in various experimental setups. Lecanemab (Mouse IgG2a) is an invaluable tool for advancing Alzheimer's disease research, offering potential insights into disease mechanisms and therapeutic interventions.
